Level C· Early human research exploring benefitsProspective StudyPubMed

Mesenchymal stem cells from human bone marrow and adipose tissue: isolation, characterization, and differentiation potentialities.

Romanov YA., Darevskaya AN., Merzlikina NV., Buravkova LB.

Prospective Study on Face & Skin, published in Bull Exp Biol Med (2005) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
Bull Exp Biol Med (2005)
Country
United States
Reported sample size
—
Source database
PubMed
PMID
16254640
DOI
10.1007/s10517-005-0430-z
Citations
119

Abstract (original English)

Comparative study of cultured human bone marrow and adipose tissue (lipoaspirate) mesenchymal stem cells was carried out. The main morphological parameters, proliferative activity, expression of surface and intracellular markers of these cells were characterized. Flow cytofluorometry and histological staining showed that both cell types exhibited similar expression of CD105, CD54, CD106, HLA-I markers, were positively stained for vimentin, ASMA, collagen-1, and fibronectin, but not HLA-DR, CD117, and hemopoietic cell markers. The cells underwent differentiation into adipocytes and osteoblasts under appropriate conditions of culturing. Incubation under neuroinductive conditions led to the appearance of a cell population positively stained for type III beta-tubulin (neuronal differentiation marker).

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
Adipose TissueBiomarkersBone Marrow CellsCell DifferentiationFlow CytometryHumansImmunohistochemistryMesenchymal Stem CellsTubulin

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research